Most importantly, a recent Phase I/II clinical trial with the reversible CXCR4 inhibitor plerixafor – a strategy named Macrophage Exclusion after Radiation Therapy or MERT – in conjunction with chemoirradiation improved local control of tumor recurrence in newly diagnosed glioblastoma patients (Thomas et al., 2019). The gene discussed is CXCR4; the disease is neoplasm.